Aim: To investigate the real-world effectiveness and safety of lemborexan for treating comorbid insomnia associated with other psychiatric disorders, and whether lemborexant helps reduce the dose of benzodiazepines (BZs).
Methods: This retrospective observational study was conducted on outpatients and inpatients treated by physicians of Juntendo University Hospital Mental Clinic between April 2020 and December 2021.
Results: Data of 649 patients who were treated with lemborexant were eventually enrolled. About 64.5% of patients were classified as the responder group. Response rates of ≥60% were recorded for most psychiatric disorders. Upon administration of lemborexant, diazepam-equivalent dose of BZs had been significantly reduced in participants (3.7 ± 8.2 vs. 2.9 ± 7.9, p < 0.001). The results of logistic regression analysis showed that outpatient (odds ratios: 2.310; 95% confidence interval [CI]: 1.32-4.05), shorter duration of BZ use (<1 year) (odds ratios: 1.512; 95% CI: 1.02-2.25), no adverse events (odds ratios: 10.369; 95% CI: 6.13-17.54), larger reduction of diazepam-equivalent dose of BZs upon introducing lemborexant prescription (odds ratios: 1.150; 95% CI: 1.04-1.27), and suvorexant was the replacement drug (odds ratios: 2.983; 95% CI: 1.44-6.19), which were significant predictors of good response.
Conclusion: Although this is a retrospective and observational study with many limitations, our study results suggest that lemborexant is effective and safe.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10091115 | PMC |
| http://dx.doi.org/10.1016/j.sleepx.2023.100070 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Association between gynecological disorders and insomnia and depression trajectories: a longitudinal study of middle-aged women.
Front Psychiatry
January 2025
Department of Gynaecology, Guang Zhou Baiyun District Maternal and Child Health Hospital, Guangzhou, China.
Background: Insomnia and depression often receive inadequate attention regarding their association with common menopausal gynecological disorders (GDs), and there is a lack of longitudinal epidemiological evidence. Furthermore, the specific disorders that exhibit the strongest correlation with depression, as well as the potential mediating role of insomnia, remain poorly understood.
Methods: Using data from the Study of Women's Health Across the Nation (SWAN) spanning 1996 to 2008, this study analyzed a sample of 2217 racially diverse premenopausal women (aged 42 to 53 at baseline).
Insomnia in Patients With Substance Use Disorders: Assessment and Management.
J Psychiatr Pract
January 2025
Department of Psychiatry and Behavioral Sciences, Emory University, Atlanta, GA.
Insomnia, characterized by difficulty initiating or maintaining sleep, or poor sleep quality, is highly prevalent among individuals with substance use disorders (SUDs). The relationship between the 2 conditions is often bidirectional. We reviewed the impact of various substances (alcohol, stimulants, opioids, and cannabis) on sleep architecture and their potential to contribute to insomnia.
View Article and Find Full Text PDFRole of metabolic characteristics in the co-occurrence of insomnia, Alzheimer's disease, and Parkinson's disease: a Mendelian randomization study.
Front Aging Neurosci
January 2025
Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
Objective: There reportedly exists a significant comorbidity between insomnia and neurodegenerative diseases, such as Alzheimer's disease (AD) and Parkinson's disease (PD), indicative of a potential link to serum metabolic dysregulation.
Method: To elucidate shared pathophysiological mechanisms between insomnia and AD/PD, we performed comprehensive two-sample Mendelian randomization (MR) analyses, investigating 1,400 serum metabolic characteristics for their causal relationships with the risks of insomnia, AD, widely defined AD (WDAD), and PD. We employed publicly available genetic data; the primary estimate was determined using inverse-variance weighting, supplemented by weighted median, simple mode, weighted mode, and the MR-PRESSO and MR-Egger methods to evaluate heterogeneity and pleiotropy.
Prevalence and associations of self-reported sleep problems in a large sample of patients with Parkinson's disease.
J Sleep Res
January 2025
Department of Psychology, Maynooth University, Maynooth, Ireland.
Sleep problems are important comorbid features of, and risk factors for, neurodegenerative diseases such as Parkinson's disease (PD). To assess the prevalence and associations of sleep problems in patients with PD we analysed data from almost 54,000 participants in the Fox Insight study, including data from 38,588 patients with PD. Sleep problems are common in PD, with ~84% of respondents with PD reporting difficulty falling or staying asleep.
View Article and Find Full Text PDFImpact and Mechanisms of Cognitive Behavioural Therapy for Insomnia on Fatigue among Cancer Survivors: A Secondary Analysis of a Randomized Controlled Trial.
Sleep
January 2025
Department of Psychology, Faculty of Science, Memorial University, St. John's, NL, Canada.
Study Objectives: Cancer-related fatigue is one of the most common symptoms in cancer survivors. Cognitive behavioural therapy for insomnia (CBT-I) can improve fatigue, but mechanisms are unclear. This secondary analysis of a randomized controlled trial evaluated whether CBT-I led to a significant improvement in fatigue, accounting for change in comorbid symptoms of insomnia, perceived cognitive impairment (PCI), anxiety, and depression.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!